|
|
| (12 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #Redirect [[High density lipoprotein classification]] |
| {{High density lipoprotein}}
| |
| {{CMG}} ; {{AE}} {{MM}}
| |
| | |
| ==Overview==
| |
| High HDL level has been defined as an increase in the serum HDL level above 60mg/dL.<ref name="pmid10662743">{{cite journal| author=Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S et al.| title=Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). | journal=Circulation | year= 2000 | volume= 101 | issue= 5 | pages= 477-84 | pmid=10662743 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10662743 }} </ref>
| |
| | |
| ==Definition==
| |
| Normally, HDL levels range from 40 mg/dL to 60 mg/dL. Based on many epidemiological studies regarding HDL, value of ≥60 mg/dL is considered high. The serum HDL level is recommended to be as high as possible, but at least ≥40 mg/dL in men, and ≥50 mg/dL in women.<ref name="pmid10662743">{{cite journal| author=Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S et al.| title=Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). | journal=Circulation | year= 2000 | volume= 101 | issue= 5 | pages= 477-84 | pmid=10662743 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10662743 }} </ref><ref name="pmid19903920">{{cite journal| author=Emerging Risk Factors Collaboration. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK et al.| title=Major lipids, apolipoproteins, and risk of vascular disease. | journal=JAMA | year= 2009 | volume= 302 | issue= 18 | pages= 1993-2000 | pmid=19903920 | doi=10.1001/jama.2009.1619 | pmc=PMC3284229 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19903920 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20157124 Review in: Ann Intern Med. 2010 Feb 16;152(4):JC-212] </ref><ref>{{cite web | url= http://eurheartjsupp.oxfordjournals.org/content/8/suppl_F/F4.full | last=Sirtori | first=Cesare R. | title=HDL and the progression of atherosclerosis: new insights | date=October 2006 | work=European Heart Journal Supplements}}</ref>
| |
| | |
| ===Guideline Resource===
| |
| https://www.aace.com/files/lipid-guidelines.pdf
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Lipopedia}}
| |
| | |
| [[Category:Lipopedia]]
| |
| [[Category:Lipid disorders]]
| |
| [[Category:Cardiology]]
| |
| [[Category:Lipoproteins]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |